About: Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.56 (-2.28%)
VALN NASDAQ Valneva SE ADR
Valneva SE ADR share price
VALN price activity
Last Price
$5.560
Change (24hr)
-0.13 USD (2.28%)
Volume
7.14K
Volume (4w avg)
-
Open
$5.75
Day Range
$5.53 - $5.75
Previous Close
$5.69
Last Trade
21 Oct, 8:00 pm GMT+0
Delayed
21 Oct, 8:00 pm GMT+0
VALN price performance
Delayed
21 Oct, 8:00 pm GMT+0
VALN Market Signals